Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-ar…
この記事を読む
一臨床医の勉強のための備忘録です。間違いなどあればご指摘を頂ければ幸いです。
この記事を読む
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-ar…
この記事を読む
PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements Yoneshima Y et al. Lung Cancer. 2…
この記事を読む
Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small Cell Lung Cancer. Morgensztern D et al. J Tho…
この記事を読む
Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer. Hendry S et al. J Thorac Oncol. 2018 Mar;13(3):367-3…
この記事を読む
High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer. …
この記事を読む
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. Raskob GE et al. N Engl J Med. 2018 Feb 15;378(7…
この記事を読む
Incidental Anterior Mediastinal Nodular Lesions on Chest CT in Asymptomatic Subjects. Yoon SH et al. J Thorac Oncol. 201…
この記事を読む
Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer. St…
この記事を読む
Combined Small Cell Carcinoma of the Lung: Is It a Single Entity? Zhao X et al. J Thorac Oncol. 2017 Oct 31. [Epub ahead…
この記事を読む
Intracerebral efficacy and tolerance of nivolumab in non–small-cell lung cancer patients with brain metastases Clément G…